Anthem Biosciences Q1 Results FY26: Q1 PAT Rises 64.84% to ₹135.79 Crore; Revenue Up 59.54% YoY
Q1 Results FY26
Updated: 18 Aug 2025 • 12:35 pm
Posted by:
Anthem Biosciences Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | ₹540.21 | ₹338.59 |
| Profit Before Tax (PBT) | ₹214.30 | ₹140.36 |
| Profit After Tax (PAT) | ₹135.79 | ₹82.38 |
(Figures in crores)
Anthem Biosciences Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | ₹538.01 | ₹338.54 |
| Profit Before Tax (PBT) | ₹223.16 | ₹142.68 |
| Profit After Tax (PAT) | ₹148.34 | ₹85.34 |
(Figures in crores)
Anthem Biosciences Q1 Results FY26 Highlights (Q1 FY26 vs FY25)
- Anthem Biosciences clocked Q1 FY26 consolidated revenue of ₹540.21 crores vs ₹338.59 crores.
- On the profit front, Anthem Biosciences earned a consolidated PAT of ₹135.79 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹82.38 crore.
- Consolidated PAT rose for the first quarter of FY26, was 64.84% YoY, and revenue rose 59.54% YoY.
- Anthem Biosciences clocked Q1 FY26 standalone revenue of ₹538.01 crores vs ₹338.54 crores.
- On the profit front, Anthem Biosciences earned a standalone PAT of ₹148.34 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹85.34 crore.
- As per the standalone figures, the quarterly PAT of Anthem Biosciences has increased by 73.83%, and revenue has increased by 58.92% YoY.
Anthem Biosciences Share Price Performance
On the opening bell of 18th August 2025, the shares of Anthem Biosciences opened at ₹823.00 per share. However, the initial gains are wiped out as of now, and Anthem Biosciences shares are trading at ₹803.70 per share, lower than their opening price.
Considering the long-term performance, Anthem Biosciences shares have yielded close to 10.15% returns in the past 1 year, and 5-year returns stand at 6.17%. Over the maximum timeframe, the Anthem Biosciences share provided 6.05% returns to investors.
What Analysts Expect Post Q1 Results?
As Anthem Biosciences has posted robust Q1 results for FY26, analysts are expecting positive trends in its share price. As per the analysts, Anthem Biosciences's share price could reach ₹1,875.00 per share in the coming year, and in downtrends, the share price could hit the level of ₹733.00 per share. However, one must ignore the risk of volatility in the stock market and invest in Anthem Biosciences shares after thorough research.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY
Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY
Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY
Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY
Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY
Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY
Recent Articles
TSMC Stock Decoded: Can the Taiwan Chipmaker Reach a $6.5 Trillion Valuation by 2030, Nearly Tripling From Today, and Is It a Buy for the Next Four Years?
2 November 2026
EAAA India Alternatives IPO Listing: Shares Debut at 0.63% Premium on NSE and BSE, Check Share Price
2 November 2026
ITI Share Price Hits 20% Upper Circuit at Rs 259.14 After Opening Flat: Up 111% in Five Years but Down 34% in a Year, So Is It Time to Book Profits or Hold?
2 November 2026
Sebi Backs Removal of LTCG for Foreign Investors, Says Report: What the Proposal Means, Why FPI Outflows Hit Rs 3.04 Lakh Crore in 2026 and What Changes for Indian Investors
2 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
TSMC Stock Decoded: Can the Taiwan Chipmaker Reach a $6.5 Trillion Valuation by 2030, Nearly Tripling From Today, and Is It a Buy for the Next Four Years?
EAAA India Alternatives IPO Listing: Shares Debut at 0.63% Premium on NSE and BSE, Check Share Price
ITI Share Price Hits 20% Upper Circuit at Rs 259.14 After Opening Flat: Up 111% in Five Years but Down 34% in a Year, So Is It Time to Book Profits or Hold?
Sebi Backs Removal of LTCG for Foreign Investors, Says Report: What the Proposal Means, Why FPI Outflows Hit Rs 3.04 Lakh Crore in 2026 and What Changes for Indian Investors
Binance Hack Explained: $6.3 Billion Stolen in 20 Minutes, About $3 Billion Frozen, FBI Names North Korea and What It Means for Bitcoin and Indian Crypto Investors
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times